(ERAS) Erasca - Ratings and Ratios

Erasca, Inc. is a clinical-stage precision oncology company dedicated to developing therapies for cancers driven by mutations in the RAS/MAPK pathway, a common driver of oncogenesis. The companys lead candidate, naporafenib, is currently in Phase 1b clinical trials for RAS Q16X solid tumors and is preparing for a pivotal Phase 3 trial in NRAS-mutant melanoma. Its pipeline also includes ERAS-007, an ERK1/2 inhibitor targeting non-small cell lung cancer (NSCLC), colorectal cancer, and advanced gastrointestinal malignancies; ERAS-601, a SHP2 inhibitor for solid tumors; and ERAS-801, a CNS-penetrant EGFR inhibitor in Phase 1 trials for recurrent glioblastoma multiforme. The company has established partnerships with Novartis for naporafenib, Katmai Pharmaceuticals for ERAS-801, and NiKang Therapeutics for ERAS-601. Headquartered in San Diego, California, Erasca was founded in 2018 and is listed on the NASDAQ under the ticker ERAS.

Based on the provided data, Erascas stock (ERAS) is expected to face headwinds over the next three months. The technical data indicates a downward trend, with the last price of $1.29 below the SMA 20 ($1.59) and SMA 50 ($2.03). The SMA 200 ($2.52) further confirms the bearish momentum. The ATR of 0.15 suggests low volatility, but the stocks resistance levels at $2.7 and $2.0 are well above current prices, indicating limited upside potential. On the fundamental side, the companys negative P/E and RoE (-35.36%) reflect ongoing losses and financial challenges, which could weigh on investor sentiment. With a market cap of $412.78M and a price-to-book ratio of 0.95, Erascas valuation appears reasonable, but the lack of positive earnings and the clinical-stage nature of its pipeline pose risks. Overall, ERAS is likely to remain under pressure, with potential support levels at $1.20 and $1.00 being tested in the near term.